Navigation Links
U.S. Genomics Awarded $9.1 Million Contract for Development of Advanced Biosensor by the U.S. Department of Homeland Security

WOBURN, Mass., July 16 /PRNewswire/ -- U.S. Genomics today announced the award of a $9.1 million contract by the U.S. Department of Homeland Security (DHS) Science and Technology Directorate. The Phase IIIX contract under the Bioagent Autonomous Networked Detectors (BAND) program will enable U.S. Genomics to continue development, testing and optimization of the company's sophisticated biological sensor for the detection of airborne pathogens using single molecule DNA mapping technology.

"The award of the Phase IIIX BAND contract further validates the potential of U.S. Genomics' single molecule based DNA mapping technology for use as a biological sensor," said John J. Canepa, Chief Executive Officer of U.S. Genomics; "The resources provided under the contract will allow us to perform extensive operational testing and to advance the capabilities of our prototype systems. These prototypes currently demonstrate the capabilities of our unique, proprietary approach to rapidly detect multiple bacterial pathogens, toxins and viruses simultaneously in an environmental sample using a single reagent set. U.S. Genomics continues to be excited about working with the outstanding team at The Department of Homeland Security Science and Technology Directorate to deliver a biosensor which meets the program's mandate to improve the security of our citizens. Additionally, our DNA mapping technology can be applied to multiple sample types for use in forensic, human diagnostic and military applications.

"U.S. Genomics' unique DNA mapping technology allows extremely precise "broadband" detection of bacterial pathogens, toxins and viruses in a biological sample. The technology's readings are sensitive to the single-molecule level and yield extremely low false positive rates. Using a universal reagent set that can detect and identify pathogens, the technology produces a genetic signature unique to each DNA fragment in the sample, and also identifies the organism from which the DNA originates. Unlike other detection technologies, U.S. Genomics' detection platform does not require amplification or the use of pathogen-specific reagents for detection of each threat organism, providing broad operational flexibility and lower costs. Furthermore, U.S. Genomics' approach has the potential to identify genetically modified species, such as those that may have been deliberately engineered to elude traditional detection methods. These factors enable greater protection in defense applications and are the foundation for new, advanced diagnostics in human infectious disease.

About U.S. Genomics, Inc.

U.S. Genomics is pioneering single molecule biology technologies for biodefense and diagnostics applications by combining advances in microfluidics, optical engineering, and novel labeling strategies. Using its DNA mapping technology, the Company is developing sophisticated biological sensors for the detection and identification of pathogens and biomarkers in the air, human serum and other biologically relevant materials. The Company's biodefense focus on airborne pathogens has been funded in part by contracts from the U.S. Department of Homeland Security Science and Technology Directorate. U.S. Genomics' portfolio of products will further a greater understanding of genetics and disease that can lead to more effective therapeutics, diagnostics, and biodefense applications. For more information, please visit

SOURCE U.S. Genomics
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Rosetta Genomics Announces Annual General Meeting of Shareholders to be Held on September 24, 2007
2. GeneNews Chief Scientist Dr. C.C. Liew co-editor of new genomics reference book
3. CODA Genomics Announces Issuance of Optimized Synthetic Gene Production Patent
4. Revolutionary Genomics Research Group Opens Boston Office; Provides DNA Evidence in Workers Comp Cases
5. ( Announces Upcoming Interview With CEO of DNAPrint Genomics
6. NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma
7. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) "Molecular Diagnostics in Cancer Therapeutic Development" Conference
8. Rosetta Genomics to Webcast Presentation at Maxim Group Growth Conference
9. BioNanoatrix and Complete Genomics Receive $8.8 Million NIST-ATP Award to Develop Sequencing Platform for $100 Genome
10. BioNanomatrix and Complete Genomics Receive $8.8 Million NIST-ATP Award to Develop Sequencing Platform for $100 Genome
11. Rosetta Genomics to Host and Webcast its R&D Day on Friday, October 26, 2007
Post Your Comments:
(Date:11/27/2015)... PUNE, India , November 27, 2015 ... --> Growing popularity of companion ... emerging in cancer biomarkers market with pharmaceutical ... develop in-demand companion diagnostic tests. ... --> Complete report on global ...
(Date:11/26/2015)... , November 26, 2015 ... device company specializing in imaging technologies, announced today that it ... as part of the Horizon 2020 European Union Framework Programme ... a large-scale clinical trial in breast cancer. , ... , --> --> The ...
(Date:11/25/2015)... Nov. 25, 2015  PharmAthene, Inc. (NYSE MKT: PIP) ... a stockholder rights plan (Rights Plan) in an effort ... carryforwards (NOLs) under Section 382 of the Internal Revenue ... PharmAthene,s use of its NOLs could be substantially ... defined in Section 382 of the Code. In general, ...
(Date:11/25/2015)... November 25, 2015 Studies reveal ... human plaque and pave the way for more effective treatment ... cats     --> ... diagnosed health problems in cats, yet relatively little was understood ... collaborative studies have been conducted by researchers from the WALTHAM ...
Breaking Biology Technology:
(Date:11/19/2015)... NEW YORK , Nov. 19, 2015  Although ... the market is dominated by a few companies, according ... Qiagen. These companies own 51% of the market share of ... report, The World Market for Molecular Diagnostic ... "The market is still controlled by one ...
(Date:11/17/2015)... -- Paris from 17 th ... Paris from 17 th until 19 th ... has invented the first combined scanner in the world which ... surface. Until now two different scanners were required: one for ... on the same surface. This innovation is an ideal ...
(Date:11/17/2015)... EASTON, Mass. , Nov. 17, 2015 ... a leader in the development and sale of broadly ... the worldwide life sciences industry, today announced it has ... of its $5 million Private Placement (the "Offering"), increasing ... to $4,025,000.  One or more additional closings are expected ...
Breaking Biology News(10 mins):